BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cadonilimab: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Akeso, RemeGen Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, RemeGen Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | RemeGen Co., Ltd. | NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therap | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05944224 A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 63 |
| 2026-12-30 est. | P1/P2 | Akeso | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 110 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | recruiting | 506 |
| 2026-10-28 est. | P3 | Akeso | NCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | NSCLC (Non-small Cell Lung Cancer) | recruiting | 560 |
| 2026-06 est. | P1/P2 | Akeso | NCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | recruiting | 280 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.